Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.530
-0.030 (-1.92%)
Apr 1, 2025, 3:47 PM EDT - Market open
Fortress Biotech Revenue
Fortress Biotech had revenue of $14.63M in the quarter ending September 30, 2024, a decrease of -7.13%. This brings the company's revenue in the last twelve months to $81.50M, up 31.51% year-over-year. In the year 2023, Fortress Biotech had annual revenue of $84.51M with 11.58% growth.
Revenue (ttm)
$81.50M
Revenue Growth
+31.51%
P/S Ratio
0.56
Revenue / Employee
$310,081
Employees
186
Market Cap
42.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
FBIO News
- 23 hours ago - Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 days ago - Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 days ago - Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 8 days ago - Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea - GlobeNewsWire
- 12 days ago - Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - GlobeNewsWire
- 15 days ago - Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform - GlobeNewsWire
- 20 days ago - Journey Medical Corporation to Participate in the 37th Annual ROTH Conference - GlobeNewsWire